» Articles » PMID: 8054448

Plasminogen Activator Inhibitor-1 in the Cerebrospinal Fluid As an Index of Neurological Disease

Overview
Date 1994 Apr 1
PMID 8054448
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a serpin proteinase inhibitor which regulates fibrinolysis and the proteinase cascade of tumour invasion. In this study, PAI-1 was identified in the cerebrospinal fluid (CSF) from patients without neurological disease and patients with various neurological disorders. The mean level of PAI-1 in the CSF of 28 patients without central nervous system (CNS) disease was 0.28 +/- 0.03 (SEM) ng/ml. CSF PAI-1 was significantly increased in the following diagnostic categories:dementia (Alzheimer's disease), cerebral infarction, CNS infection, alcohol withdrawal seizures and CNS neoplasia. In all these disorders, with the exception of CNS infection, PAI-1 was also increased as a fraction of total CSF protein. CSF PAI-1 was not increased in patients with hydrocephalus or idiopathic seizure disorders. Complementary plasma samples were available for 18 of the 128 CSF specimens studied. For these cases, there was no correlation between plasma PAI-1 and CSF PAI-1 levels. PAI-1 may represent a non-specific marker of disease in the central nervous system.

Citing Articles

Molecular and Functional Alterations in the Cerebral Microvasculature in an Optimized Mouse Model of Sepsis-Associated Cognitive Dysfunction.

Avila-Gomez P, Shingai Y, Dash S, Liu C, Callegari K, Meyer H eNeuro. 2024; 11(9).

PMID: 39266325 PMC: 11439565. DOI: 10.1523/ENEURO.0426-23.2024.


Plasminogen activator inhibitor-1 mediates cerebral ischemia-induced astrocytic reactivity.

Yanev P, Martin-Jimenez C, Vesga-Jimenez D, Zvinys L, Weinrich N, Cree M J Cereb Blood Flow Metab. 2024; 45(1):102-114.

PMID: 39113414 PMC: 11572231. DOI: 10.1177/0271678X241270445.


Pharmacological inhibition of plasminogen activator inhibitor-1 prevents memory deficits and reduces neuropathology in APP/PS1 mice.

Rodriguez G, Eren M, Haupfear I, Viola K, Cline E, Miyata T Psychopharmacology (Berl). 2023; 240(12):2641-2655.

PMID: 37700086 DOI: 10.1007/s00213-023-06459-8.


Early therapeutic effects of an Angiopoietin-1 mimetic peptide in middle-aged rats with vascular dementia.

Gao H, Findeis E, Culmone L, Powell B, Landschoot-Ward J, Zacharek A Front Aging Neurosci. 2023; 15:1180913.

PMID: 37304071 PMC: 10248134. DOI: 10.3389/fnagi.2023.1180913.


Review of evidence implicating the plasminogen activator system in blood-brain barrier dysfunction associated with Alzheimer's disease.

Tang M, Gorin F, Lein P Ageing Neurodegener Dis. 2022; 2.

PMID: 35156107 PMC: 8830591. DOI: 10.20517/and.2022.05.